» Articles » PMID: 2476893

Antibodies to Synthetic Peptides from the PreS1 Region of the Hepatitis B Virus (HBV) Envelope (env) Protein Are Virus-neutralizing and Protective

Overview
Journal Vaccine
Date 1989 Jun 1
PMID 2476893
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatitis B virus (HBV) envelope (env) proteins contain three antigenic domains designated S, preS2 and preS1. Studies with synthetic peptide immunogens demonstrated the role of preS2 epitopes in protection against HBV infection. The preS1 domain is implicated in virus-cell receptor interactions suggesting that anti-preS1-specific antibodies should neutralize the infectivity of HBV by blocking virus attachment to cells. We present here evidence that an antiserum to a peptide from the preS1 sequence, anti-preS(21-47), is virus-neutralizing and that active immunization of chimpanzees with a longer peptide derived from the preS1 sequence, preS(12-47), elicits antibodies protective against HBV infection. These results establish the role of the preS1 domain in the process of virus neutralization and the potential of synthetic preS1 analogues for hepatitis B vaccination.

Citing Articles

A Multivalent mRNA Therapeutic Vaccine Exhibits Breakthroughs in Immune Tolerance and Virological Suppression of HBV by Stably Presenting the Pre-S Antigen on the Cell Membrane.

Liu S, Wang J, Li Y, Wang M, Du P, Zhang Z Pharmaceutics. 2025; 17(2).

PMID: 40006578 PMC: 11859219. DOI: 10.3390/pharmaceutics17020211.


Hepatitis B virus entry, assembly, and egress.

Chuang Y, Ou J Microbiol Mol Biol Rev. 2024; 88(4):e0001424.

PMID: 39440957 PMC: 11653734. DOI: 10.1128/mmbr.00014-24.


Both middle and large envelope proteins can mediate neutralization of hepatitis B virus infectivity by anti-preS2 antibodies: escape by naturally occurring preS2 deletions.

Zhang J, Wang Q, Yuan W, Li J, Yuan Q, Zhang J J Virol. 2024; 98(8):e0192923.

PMID: 39078152 PMC: 11334434. DOI: 10.1128/jvi.01929-23.


Hepatitis B Surface Antigen Isoforms: Their Clinical Implications, Utilisation in Diagnosis, Prevention and New Antiviral Strategies.

Lazarevic I, Banko A, Miljanovic D, Cupic M Pathogens. 2024; 13(1).

PMID: 38251353 PMC: 10818932. DOI: 10.3390/pathogens13010046.


Pathogenicity and virulence of Hepatitis B virus.

Chuang Y, Tsai K, Ou J Virulence. 2022; 13(1):258-296.

PMID: 35100095 PMC: 8812780. DOI: 10.1080/21505594.2022.2028483.